Moderna, Inc.

NASDAQ:MRNA

Biotechnology

Healthcare
$196.79 +4.01%

+$2.48 today

Market cap
$79.63B
Beta
1.03
P/E (TTM)
-7.9
EPS (TTM)
-$8.09
52W Low $22.28High $67.74

Volume 6.91M

Average 6.53M

MRNA Net Income

Bottom-line profit after all expenses, interest, and taxes.

Moderna, Inc.NASDAQ: MRNA

Net Income · Q3 FY2026 · quarter ended Sep 2026

Net income turns positive

Q3 FY2026 net income was $162M, compared with -$200M a year earlier. Trailing-twelve-month net income was -$2.79B.

Context

  • Net income amounted to 145.2% of revenue in FY2025, up 33.8 pp from a year earlier.
  • Net income increased in 2 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 14 analysts of -$2.89B (-2.4%) for the fiscal year ending Dec 2026, a slowdown from the +20.8% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
$162M+120.7% QoQ
Last fiscal yearDec 2025
-$2.82B+20.8% YoY
LTMSep 2026
-$2.79B+10.5% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+181.0%-8.4%-189.4 pp
1 year+20.8%-2.4%-23.2 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the income statement

Latest · FY2025
(2.82B) USD
Year-over-year change
+20.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How MRNA compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +10.5% is the 4th highest of 10, against a peer median of -59.7%.
  • Net income amounts to 110.5% of revenue for MRNA, versus a peer median of 64.0%.
MRNA Competitors
Net Income for MRNA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GSKGSK plcLTM Jun 2026£4.82B GBP+40.8%-27.4%14.5%
PFEPfizer Inc.LTM Jun 2026$4.33B USD-59.7%-37.2%6.8%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026-$78.67M USD-15.4%—173.5%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026-$84.93M USD+12.0%——
NVAXNovavax, Inc.LTM Mar 2026-$87.84M USD-118.3%—14.7%
VALNValneva SELTM Mar 2026-€138.03M EUR-71.7%—88.3%
VIRVir Biotechnology, Inc.LTM Mar 2026-$442.72M USD+23.4%—676.0%
PCVXVaxcyte, Inc.LTM Jun 2026-$1.06B USD-94.4%——
BNTXBioNTech SELTM Jun 2026-€1.69B EUR-390.8%—64.0%
MRNAModerna, Inc.LTM Sep 2026-$2.79B USD+10.5%—110.5%
Peer median (excluding MRNA) —-59.7%-32.3%64.0%

Competitors are the stored peer set for MRNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue17.74B18.88B6.85B3.2B1.94B
Cost of Revenue2.62B5.42B4.69B1.46B868M
Gross Profit15.12B13.46B2.16B1.74B1.08B
Gross Margin85.2%71.3%31.5%54.2%55.3%
Research & Development1.99B3.3B4.85B4.54B3.13B
Selling, General & Admin567M1.13B1.55B1.17B1.02B
Operating Expenses1.82B4.04B6.39B5.68B4.15B
Depreciation & Amortization232M348M621M189M215M
EBITDA13.54B9.95B(3.28B)(3.39B)(2.55B)
EBITDA Margin76.3%52.7%-47.9%-106.1%-131.3%
Operating Income13.3B9.42B(4.24B)(3.95B)(3.07B)
Operating Margin75.0%49.9%-61.9%-123.3%-158.1%
Interest Income18M200M421M425M314M
Interest Expense18M29M38M24M10M
Other Income / Expenses(11M)155M297M338M306M
Income Before Tax13.29B9.58B(3.94B)(3.61B)(2.77B)
Pre-Tax Margin74.9%50.7%-57.6%-112.8%-142.4%
Income Tax Expense1.08B1.21B772M(46M)54M
Net Income12.2B8.36B(4.71B)(3.56B)(2.82B)
Net Margin68.8%44.3%-68.8%-111.3%-145.2%
EPS (Basic)30.3121.26(12.34)(9.27)(7.26)
EPS (Diluted)28.2920.10(12.34)(9.27)(7.26)
Weighted Avg Shares403M394M382M384M389M
Weighted Avg Shares (Diluted)431M416M382M384M389M

Moderna, Inc.

NASDAQ:MRNA

Intrinsic Alpha fair value

Locked

Current Price

$196.79

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.